Rockefeller Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$61.8K Buy
8,051
+4,870
+153% +$47.7K ﹤0.01% 3343
2026
Q2
$31.2K Sell
3,181
-2,776
-47% -$25.2K ﹤0.01% 3574
2026
Q1
$50.5K Buy
5,957
+3,385
+132% +$32.3K ﹤0.01% 3270
2025
Q4
$31.2K Buy
+2,572
New +$31.2K ﹤0.01% 3288

Other funds holding OCUL

Rockefeller Capital Management's OCUL Position: Q3 2026 in Review

Rockefeller Capital Management increased its Ocular Therapeutix (OCUL) stake by 153% in Q3 2026, buying an estimated $47.7K and bringing the position to 8,051 shares worth $61.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3343.

Rockefeller Capital Management first reported a position in OCUL in Q4 2025 and has held it in 4 quarters since. 263 funds tracked by Wall St. Rank hold OCUL as of Q3 2026.

  • Rockefeller Capital Management held 8,051 shares of Ocular Therapeutix worth $61.8K as of Q3 2026.
  • Rockefeller Capital Management bought 4,870 Ocular Therapeutix shares in Q3 2026, an estimated $47.7K.
  • Ocular Therapeutix made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3343 holding.
  • Rockefeller Capital Management first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 4 quarters since.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.